A Phase 2b, Multicenter, Double-Blind, Randomized, Placebo-controlled Trial Evaluating Efficacy and Safety of Subcutaneous Doses of Navepegritide Administered Once Weekly for 52 Weeks in Adolescents (12-18 Years of Age) With Achondroplasia.

The purpose of this clinical trial is to evaluate efficacy and safety of once weekly subcutaneous (SC) doses of navepegritide 100 μg/kg compared to placebo (inactive drug) in adolescents aged 12 to 18 years with Achondroplasia. What will be measured is Annualized Growth Velocity after a 52-week treatment period.

开始日期2024-12-10

申办/合作机构

Ascendis Pharma A/S

NCT06433557

/ Active, not recruiting临床2期

A Phase 2, Open-Label, Single-Arm, 156-week Trial to Investigate the Efficacy, Safety and Tolerability of Combined Once Weekly Navepegritide and Lonapegsomatropin in Children With Achondroplasia

This proof-of-concept trial is being conducted to evaluate the efficacy, safety and tolerability of combination treatment with navepegritide and lonapegsomatropin administered as separate subcutaneous (SC) injections once weekly in children with achondroplasia (ACH) aged 2 to 11 years.

开始日期2024-07-26

申办/合作机构

Ascendis Pharma Growth Disorders A/S

CTIS2023-508341-40-00

/ Not yet recruiting临床2期

COACH: A Phase 2, Open-Label, Single-Arm, 156-week Trial to Investigate the Efficacy, Safety and Tolerability of Combined Once Weekly Navepegritide and Lonapegsomatropin in Children with Achondroplasia - ASND0042

开始日期2024-07-26

申办/合作机构

Ascendis Pharma Growth Disorders A/S

100 项与 Navepegritide 相关的临床结果

登录后查看更多信息

100 项与 Navepegritide 相关的转化医学

登录后查看更多信息

100 项与 Navepegritide 相关的专利（医药）

登录后查看更多信息

项与 Navepegritide 相关的文献（医药）

2024-11-01·Expert Review of Endocrinology & Metabolism

Progress in managing children with achondroplasia

Review

作者: Savarirayan, Ravi ; Taylor-Miller, Tashunka

INTRODUCTION:

Achondroplasia is a heritable disorder of the skeleton that affects approximately 300,000 individuals worldwide. Until recently, treatment for this condition has been purely symptomatic. Efficacious treatment options for children are now approved or are in clinical trials.

AREAS COVERED:

This review discusses key advances in the therapeutic management of children with achondroplasia, including vosoritide, the first approved drug, and other emerging precision therapies. These include navepegritide, a long-acting form of C-type natriuretic peptide, and infigratinib, a tyrosine kinase receptor inhibitor, summarizing trial outcomes to date.

EXPERT OPINION:

The advent of the first approved precision therapy for achondroplasia in vosoritide has been a paradigm shifting advance for children affected by this condition. In addition to changing their natural growth history, it is hoped that it will decrease their medical complications and enhance functionality. These new treatment options highlight the importance of prompt prenatal identification and subsequent testing of a suspected fetus with achondroplasia and counseling of families. It is hoped that, in the near future, families will have the option to consider a range of effective targeted therapies that best suit their child with achondroplasia, starting from birth should they choose.

2023-11-01·EClinicalMedicine

Once-weekly TransCon CNP (navepegritide) in children with achondroplasia (ACcomplisH): a phase 2, multicentre, randomised, double-blind, placebo-controlled, dose-escalation trial

Article

作者: Ma, Nina S ; Zarate, Yuri A ; Savarirayan, Ravi ; Mao, Meng ; Winding, Bent ; Sousa, Sérgio B ; McDonnell, Ciara ; Bober, Michael B ; Hoernschemeyer, Daniel G ; Bacino, Carlos A ; Smith, Alden ; Legare, Janet M ; Volck, Birgitte ; Schnabel, Dirk ; Chakraborty, Mukta ; Hofman, Paul L ; Ljungberg, Merete ; Giwa, Adebola ; White, Klane K ; Shu, Aimee D ; Högler, Wolfgang ; Quattrin, Teresa ; Abuzzahab, M Jennifer

Background:

TransCon CNP (navepegritide) is an investigational prodrug of C-type natriuretic peptide (CNP) designed to allow for continuous CNP exposure with once-weekly dosing. This 52-week phase 2 (ACcomplisH) trial assessed the safety and efficacy of TransCon CNP in children with achondroplasia.

Methods:

ACcomplisH is a global, randomised, double-blind, placebo-controlled, dose-escalation trial. Study participants were recruited between June 10, 2020, and September 24, 2021. Eligible participants were prepubertal, aged 2-10 years, with genetically confirmed achondroplasia, and randomised 3:1 to once-weekly subcutaneous injections of TransCon CNP (6, 20, 50, or 100 μg CNP/kg/week) or placebo for 52 weeks. Primary objectives were safety and annualised growth velocity (AGV). ACcomplisH is registered with ClinicalTrials.gov (NCT04085523) and Eudra (CT 2019-002754-22).

Findings:

Forty-two participants received TransCon CNP at doses of 6 μg (n = 10; 7 female), 20 μg (n = 11; 3 female), 50 μg (n = 10; 3 female), or 100 μg (n = 11; 6 female) CNP/kg/week, with 15 receiving placebo (5 female). Treatment-emergent adverse events (TEAEs) were mild or moderate with no grade 3/4 events reported. There were 2 serious TEAEs that were assessed as not related to TransCon CNP. Eleven injection site reactions occurred in 8 participants receiving TransCon CNP and no symptomatic hypotension occurred. TransCon CNP demonstrated a dose-dependent improvement in AGV. At 52 weeks, TransCon CNP 100 μg CNP/kg/week significantly improved AGV vs placebo (least squares mean [95% CI] 5.42 [4.74-6.11] vs 4.35 [3.75-4.94] cm/year; p = 0.0218), and improved achondroplasia-specific height SDS from baseline (least squares mean [95% CI] 0.22 [0.02-0·41] vs -0·08 [-0.25 to 0.10]; p = 0.0283). All participants completed the randomised period and continued in the ongoing open-label extension period receiving TransCon CNP 100 μg CNP/kg/week.

Interpretation:

This phase 2 trial suggests that TransCon CNP is effective, safe, with low injection site reaction frequency, and may provide a novel, once-weekly treatment option for children with achondroplasia. These results support TransCon CNP at 100 μg CNP/kg/week in the ongoing pivotal trial.

Funding:

Ascendis Pharma, A/S.

2022-11-01·BRITISH JOURNAL OF CLINICAL PHARMACOLOGY2区 · 医学

Phase 1 safety, tolerability, pharmacokinetics and pharmacodynamics results of a long‐acting C‐type natriuretic peptide prodrug, TransCon CNP

2区 · 医学

Article

作者: Christoffersen, Eva Dam ; Breinholt, Vibeke Miller ; Mygind, Per Holse ; Ota, Sho ; Will Charlton, R. ; Zhang, Ying ; Viuff, Dorthe

Aim:

TransCon CNP is a novel prodrug designed to provide sustained release of C‐type natriuretic peptide (CNP) for once‐weekly therapy, addressing the pathology leading to aberrant skeletal development in achondroplasia. This phase 1 trial was initiated to assess the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of TransCon CNP.

Methods:

This randomized, placebo‐controlled, single‐ascending dose phase 1 trial was performed at two sites in Australia and enrolled 45 healthy adult males. Subjects received placebo or TransCon CNP (single‐ascending dose cohorts [3, 10, 25, 75 or 150 μg CNP/kg]). The primary endpoint was frequency of adverse events and other safety outcomes. Other endpoints included PK and PD measured by cyclic guanosine‐monophosphate (cGMP) and amino‐terminal propeptide of CNP (NTproCNP).

Results:

TransCon CNP provided continuous systemic exposure to CNP over at least 7 days post‐dose. Plasma and urine levels of cGMP were significantly increased in subjects administered TransCon CNP at 75‐150 μg CNP/kg, indicating target engagement of active CNP at the natriuretic peptide receptor‐B (NPR‐B) for at least 1 week post‐dose. TransCon CNP was well‐tolerated, with no serious treatment‐emergent adverse events or discontinuations. Extensive cardiac safety assessments did not reveal any clinically relevant effects on electrocardiogram parameters, including heart rate, PR, QRS and QTcF intervals.

Conclusions:

Safety and PD data from this phase 1 trial support that TransCon CNP is well tolerated, with a PK profile compatible with a once‐weekly dosing regimen. Further studies are ongoing to evaluate the potential of TransCon CNP to positively impact abnormal endochondral ossification in children with achondroplasia.

项与 Navepegritide 相关的新闻（医药）

2025-04-01

·PipelineReview

Ascendis Submits U.S. NDA for TransCon CNP (Navepegritide) for the Treatment of Children with Achondroplasia

— Data demonstrated multiple clinical benefits beyond linear growth — NDA supported by data from three randomized, double-blind, placebo-controlled clinical trials in children with achondroplasia, with up to three years of open-label extension data — MAA in EU on track for submission during Q3 2025 COPENHAGEN, Denmark I March 31, 2025 I Ascendis Pharma A/S (Nasdaq: ASND) today announced that it has submitted its New Drug Application (NDA) to the U.S. Food & Drug Administration (FDA) for TransCon CNP (navepegritide) for the treatment of children with achondroplasia. TransCon CNP is an investigational prodrug of C-type natriuretic peptide (CNP) administered once weekly and designed to treat individuals with achondroplasia by providing continuous exposure of active CNP to receptors on tissues throughout the body, including growth plates and skeletal muscle. The filing is based on data from three randomized, double-blind, placebo-controlled clinical trials and up to three years of open-label extension data, including results from the pivotal ApproaCH Trial of children with achondroplasia. “We are pleased to share clinical data with the FDA demonstrating that, in addition to increased growth velocity, treatment with TransCon CNP was associated with reduced health-related burden, stronger muscle function, and straightening of abnormal leg bowing for the majority of treated children,” said Aimee Shu, M.D., Executive Vice President and Chief Medical Officer at Ascendis Pharma. “In addition to once-weekly administration, these outcomes and a safety and tolerability profile comparable to placebo support TransCon CNP’s potential to be recognized as a best-in-class treatment for achondroplasia.” Ascendis is on track to submit its Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) during Q3 2025. About Achondroplasia Achondroplasia is a rare genetic condition arising from a systemic fibroblast growth factor receptor 3 (FGFR3) variant that leads to an imbalance in the effects of the FGFR3 and CNP signaling pathways, estimated to affect more than 250,000 people worldwide. While historically considered a bone growth disorder, the FGFR3 variant seen in achondroplasia is expressed in tissues throughout the body, causing serious muscular, neurological, and cardiorespiratory complications in addition to skeletal dysplasia. Medical complications of achondroplasia vary across different stages of life. Throughout infancy and childhood, observed complications include spinal deformities, enlarged brain ventricles, impaired muscle strength and stamina, hearing deficits and chronic ear infections, upper airway obstructions, sleep-disordered breathing, hip problems, leg bowing, and chronic pain; many of these persist or worsen in adulthood. These medical complications can have detrimental effects on quality of life, physical functioning, and psychosocial function. Individuals with achondroplasia often require multiple surgeries and procedures to alleviate the condition’s many complications. About Ascendis Pharma A/S Ascendis Pharma is a global biopharmaceutical company focused on applying our innovative TransCon technology platform to make a meaningful difference for patients. Guided by our core values of Patients, Science, and Passion, and following our algorithm for product innovation, we apply TransCon to develop new therapies that demonstrate best-in-class potential to address unmet medical needs. Ascendis is headquartered in Copenhagen, Denmark and has additional facilities in Europe and the United States. Please visit ascendispharma.com to learn more. SOURCE: Ascendis Pharma

申请上市临床结果

2025-03-24

·CPHI制药在线

维昇药业上市背后，不止是“生长发育第一股”

关注并星标CPHI制药在线 3月21日，维昇药业在第四次向港交所递交IPO文件后，终于顺利“敲钟”，成为“港股生长发育第一股”。事实上，无论是运营模式还是管线产品，维昇药业都有值得业界学习的地方。　反向Newco标杆维昇药业成立于2018年，由丹麦药企Ascendis Pharma A/S（下称Ascendis）、维梧资本和Sofinnova Ventures共同在上海创立。其中Ascendis以产品入股，维梧资本和Sofinnova Ventures出资支持。这一模式与近两年来国内涌现的NewCo模式不同。作为一种复杂的创新药资产交易模式，传统NewCo是指新公司由境外资本出资设立，在获得中国药企许可的管线权益后，向NewCo公司提供资金并负责经营管理，中国药企除了获得管线的授权许可费外，还可以获得NewCo公司的部分股权，NewCo公司今后独立在境外IPO或公司/管线被MNC并购。而维昇药业这种借助海外药企技术+本土化运营的模式，与传统NewCo模式恰恰相反，这一新颖模式被形象地称为反向NewCo。　专注内分泌领域，避开红海市场根据维昇药业与Ascendis的达成独家许可协议，公司能够在相关地区开发、生产和商业化隆培促生长素（lonapegsomatropin）、那韦培肽（navepegritide）及帕罗培特立帕肽（palopegteriparatide）等内分泌领域的候选药物，这三款药物也是维昇药业的核心产品。与扎堆内卷PD-1、GLP-1等大赛道的药企不同，维昇药业从一开始就避开这些红海市场，专注内分泌疾病领域。据弗若斯特沙利文数据，预计到2026年，中国的非糖尿病类内分泌药物市场规模将增至68亿美元；到2030年将增至115亿美元。与此同时，目前至少有近一半的内分泌疾病缺乏有效的治疗手段。以隆培促生长素为例，这是一款每周一次的长效生长激素替代疗法。已获FDA及欧盟EMA批准上市，用于治疗儿童生长激素缺乏症（PGHD）。 GHD是一种因下丘脑-垂体轴的器质性病变或功能性异常导致生长激素缺乏引起的疾病，患者表现为身材矮小、代谢异常、认知缺陷和生活质量差等问题。据相关媒体报道，我国4-15岁的人群矮小症发病人数有700万，但每年就诊人数预估不足30万人，接受规范治疗的患者渗透率仍然远远低于欧美国家。对于PGHD来说，补充生长激素是目前公认的最有效方法之一。生长激素是由脑垂体前叶嗜酸性细胞分泌的一种长度为191个氨基酸的肽类激素，通过刺激肝脏等组织产生胰岛素样生长因子（IGF -1）发挥生理功能，促进骨骼生长，促进蛋白质合成，调节脂肪、糖、矿物质代谢等。目前，国内已上市的生长激素产品，还是以短效类产品为主，高端的长效类产品仅获批一款——金赛增（金赛药业，长春高新子公司），患者的需求远没有得到充分满足。预计2030年，长效生长激素将是PGHD的主要疗法，市场份额占比可达74%。隆培促生长素基于维昇药业的暂时连接技术（TransCon），被设计为每周一次给药方案，并在体内释放未经修饰的与人内源性生长激素相同的分子，保留了原始作用机制。据国内III期临床试验数据显示，隆培促生长素的年化生长速率为10.66厘米/年，优于传统短效制剂的9.75厘米/年，达到研究主要终点。基于该III期临床试验，2024年3月，隆培促生长素在国内的上市许可申请（BLA）获得中国国家药监局受理，预计于2025年在中国上市。值得一提的是，隆培促生长素海外上市以来，销量一路攀升。2024年，其销售额达到2.02亿欧元（约14.7亿元人民币），同比增长高达84%。另一款核心产品那韦培肽，是一款C型利钠肽的长效前药，每周一次给药，拟开发用于治疗2至10岁软骨发育不全患者，该患者群体在国内有超过5万人。据国内II期临床试验显示，在治疗第52周时，剂量为100μg/kg/周的队列的那韦培肽的AGV（5.939厘米/年）较安慰剂（4.760厘米/年）高。帕罗培特立帕肽是一种甲状旁腺激素替代疗法，每日一次，拟开发用于治疗慢性甲状旁腺功能减退症，该病由于甲状旁腺激素分泌减少或功能缺陷，引起钙磷代谢异常。在一项III期关键试验中，经过长达156周的治疗，77.6%（45/58）接受帕罗培特立帕肽治疗的患者达到了主要终点（界定为在治疗第26周时，符合下列要求的受试者比例：白蛋白校正血清钙浓度在正常范围内，停用骨化三醇或阿法骨化醇活性维生素D，且停用治疗剂量的钙，在26周随访前的4周内未增加研究药物的剂量），而对照组中0.0%（0/22）的患者达到了主要终点。早在2023年9月，国家卫生健康委等6部门联合制定了《第二批罕见病目录》，软骨发育不全和遗传性甲状旁腺功能减退症均被纳入其中，意味着该类疾病将得到全方位的政策支持。除了在内分泌蓝海市场布局产品管线外，维昇药业的TransCon（Transient Conjugation，暂时连接）平台深受药企关注。　独一无二的技术平台，引诺和诺德押注为了攻克肽类激素（如生长激素等）长效化的壁垒，维昇药业开发了TransCon（Transient Conjugation，暂时连接）技术平台，TransCon分子包括三个部分：未经修饰的原型药物，保护原型药物的惰性载体分子和将两者暂时连接起来的连接体。当3部分结合后，形成前药，其载体分子可以使得原型药物以无活性状态存在，不被机体清除。当前药注射至人体内，在生理条件的PH和体温下，有活性的、未经修饰的原型药物将以可控的方式释放出来，从而实现了从短效到长效的突破。 2024年11月，维昇药业宣布授予诺和诺德TransCon技术平台的全球独家许可，以开发、制造和商业化诺和诺德在代谢性疾病（包括肥胖和2型糖尿病）方面的产品等。维昇药业将有资格获得高达2.85亿美元的预付款、开发和监管里程碑付款，以及基于销售额的里程碑付款和全球净销售额的分层特许权使用费等。该合作的达成肯定了TransCon在长效化技术方面的优势。维昇药业通过反向NewCo落地中国，如今凭借核心产品和技术平台在港股上市，未来公司将有望以全方位的优势，缔造内分泌赛道全新的传奇。参考资料：　 1.维昇药业招股书 https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0313/2025031300018_c.pdf. 2.https://www.hsppharma.com/news/pfizer-once-a-week-long-acting-drug-somatrogon-38750405.html. 3.Miller BS, Yuen KCJ. Spotlight on Lonapegsomatropin Once-Weekly Injection and Its Potential in the Treatment of Growth Hormone Deficiency in Pediatric Patients. Drug Des. END 2025金笔奖征文活动开启，来投稿吧！领取CPHI & PMEC China 2025展会门票智药研习社直播预告来源：CPHI制药在线声明：本文仅代表作者观点，并不代表制药在线立场。本网站内容仅出于传递更多信息之目的。如需转载，请务必注明文章来源和作者。投稿邮箱：Kelly.Xiao@imsinoexpo.com ▼更多制药资讯，请关注CPHI制药在线▼ 点击阅读原文，进入智药研习社~

IPO上市批准并购申请上市

2025-03-21

·FiercePharma

Biotech designed to commercialize Ascendis' endocrinology drugs in China files $86M IPO

Visen Pharmaceuticals is designed to develop and commercialize Ascendis’ endocrinology therapies in greater China. Endocrine-disease-focused Visen Pharmaceuticals is making its public market debut in Hong Kong, filing papers for an $86.5 million IPO.The China-based biotech was formed in 2018 by Ascendis Pharma and an investor syndicate led by Vivo Capital. The biotech is designed to develop and commercialize Ascendis’ endocrinology therapies in greater China.Now, Visen is going public, with expected gross proceeds of $100 million, according to March 20 regulatory filings (PDF). The company has previously raised about $190 million, closing a $150 million series B financing in early 2021. That fundraise included OrbiMed, Logos Capital, Ascendis Pharma, Vivo Capital and Sofinnova Investments, among others.The company hosts three programs in its pipeline: Yorvipath (palopegteriparatide) for adults with chronic hypoparathyroidism; Skytrofa (lonapegsomatropin) for pediatric growth hormone deficiency; and navepegritide, an investigational prodrug of C-type natriuretic peptide for achondroplasia.

IPO

100 项与 Navepegritide 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
软骨发育不全	申请上市	美国	Ascendis Pharma A/S	2025-03-31

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05598320 (ApproaCH, PipelineReview) 人工标引	临床2/3期	软骨发育不全	84	TransCon CNP (ages 2-11 years)	範觸憲積製鹹遞夢鏇築(鏇繭夢淵淵網製觸憲窪) = 蓋範選醖鹽餘齋壓齋衊顧鏇積窪壓觸衊壓蓋膚 (壓蓋蓋鹹積獵遞網淵夢 ) 更多	积极	2024-09-16
				Placebo (ages 2-11 years)	範觸憲積製鹹遞夢鏇築(鏇繭夢淵淵網製觸憲窪) = 顧壓壓壓獵繭築觸蓋構顧鏇積窪壓觸衊壓蓋膚 (壓蓋蓋鹹積獵遞網淵夢 ) 更多
NCT04085523 (ACcomplisH, Company_Website) 人工标引	临床2期	软骨发育不全	57	TransCon CNP	鏇網構憲製壓獵構鑰鬱(鏇觸醖顧鑰憲壓餘鹽窪) = patients treated for one year at the pivotal 100μg/kg/week dose demonstrated significant improvements in well-being and physical functioning compared to placebo. 窪廠衊窪襯簾鏇蓋糧製 (蓋齋蓋襯選觸遞觸繭糧 ) 更多	积极	2024-06-24
				Placebo
NCT04085523 (ACcomplisH, CTgov)	临床2期	软骨发育不全	57	TransCon CNP (TransCon CNP 6 mcg)	鹽窪齋簾廠獵選製選艱(網夢壓蓋鏇壓願鹽構淵) = 顧蓋繭膚襯糧衊築顧糧顧鹽糧鑰簾夢構鹹淵繭 (廠積憲蓋積餘齋齋顧衊, 簾艱糧夢窪鑰廠壓鬱壓 ~ 鹽製鹽艱網淵壓製鏇廠) 更多	-	2024-03-07
				TransCon CNP (TransCon CNP 20 mcg)	鹽窪齋簾廠獵選製選艱(網夢壓蓋鏇壓願鹽構淵) = 鹹衊壓夢齋範蓋衊築遞顧鹽糧鑰簾夢構鹹淵繭 (廠積憲蓋積餘齋齋顧衊, 鑰鹹餘廠網顧廠遞膚網 ~ 膚蓋艱顧襯願衊齋襯蓋) 更多
NCT04085523 \| NCT05598320 (ACcomplisH, GlobeNewswire) 人工标引	临床2期	软骨发育不全	-	TransCon CNP 100 µg/kg/week	淵顧選蓋襯顧遞獵襯鹹(築壓淵憲醖淵選網積餘): P-Value = 0.002 更多	积极	2023-12-20
				placebo
NCT05246033 (ACcomplisH China, PRNewswire) 人工标引	临床2期	软骨发育不全	24	TransCon CNP 50μg/kg/week	鹹構網鏇齋窪膚壓選製(獵積顧繭窪憲糧網繭鑰) = 壓廠鏇鬱醖艱廠積蓋壓壓選蓋襯艱鹽觸簾顧簾 (鑰積鏇憲鑰願觸齋簾餘 ) 达到	积极	2023-11-16
				TransCon CNP 100μg/kg/week	鹹構網鏇齋窪膚壓選製(獵積顧繭窪憲糧網繭鑰) = 構遞構選積齋齋積繭夢壓選蓋襯艱鹽觸簾顧簾 (鑰積鏇憲鑰願觸齋簾餘 ) 达到
NCT04085523 (ACcomplisH, Pubmed)	临床2期	软骨发育不全	42	TransCon CNP 100 μg CNP/kg/week	網鬱選夢蓋獵醖醖鹽憲(衊範鏇窪網觸窪鏇憲齋) = 鹽鹽獵鏇構鏇膚鹹襯遞簾窪構襯顧膚蓋顧鑰範 (廠顧糧遞憲廠糧夢窪築, 4.74 ~ 6.11)	积极	2023-11-01
				Placebo	網鬱選夢蓋獵醖醖鹽憲(衊範鏇窪網觸窪鏇憲齋) = 鏇觸憲築築築鏇廠夢製簾窪構襯顧膚蓋顧鑰範 (廠顧糧遞憲廠糧夢窪築, 3.75 ~ 4.94)
NCT05598320 (ACcomplisH, ENDO2023)	临床2期	软骨发育不全	57	TransCon CNP 6 μg/kg/week	繭憲繭鹽繭網糧選範醖(觸範觸夢憲鬱網醖鹽顧) = 膚廠獵網鹹壓觸製鹽鑰鏇鏇壓遞憲憲繭網醖範 (網積夢衊壓艱鏇遞選網 )	积极	2023-10-05
				TransCon CNP 20 μg/kg/week	繭憲繭鹽繭網糧選範醖(觸範觸夢憲鬱網醖鹽顧) = 鹽襯觸簾鏇憲簾選糧壓鏇鏇壓遞憲憲繭網醖範 (網積夢衊壓艱鏇遞選網 )